FDA grants priority review to J&J's IMAAVY for rare blood disorder
The U.S. Food and Drug Administration granted Priority Review to Johnson & Johnson's (NYSE: JNJ) supplemental biologics license application for ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)